Lixte Biotechnology (NASDAQ:LIXT) Stock Price Down 4.6% – Here’s What Happened

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT)’s stock price was down 4.6% during mid-day trading on Monday . The company traded as low as $3.34 and last traded at $3.4450. Approximately 7,821 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 46,207 shares. The stock had previously closed at $3.61.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Lixte Biotechnology in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Lixte Biotechnology Price Performance

The firm has a market capitalization of $40.03 million, a PE ratio of -2.78 and a beta of 0.93. The company’s fifty day simple moving average is $2.97 and its 200 day simple moving average is $3.66.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Axxcess Wealth Management LLC bought a new stake in Lixte Biotechnology during the 4th quarter valued at $54,000. XTX Topco Ltd bought a new position in shares of Lixte Biotechnology in the fourth quarter worth $57,000. Geode Capital Management LLC grew its position in shares of Lixte Biotechnology by 25.9% in the fourth quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock valued at $205,000 after purchasing an additional 10,722 shares in the last quarter. DRW Securities LLC grew its position in shares of Lixte Biotechnology by 11.6% in the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after purchasing an additional 5,645 shares in the last quarter. Finally, Federation des caisses Desjardins du Quebec raised its stake in shares of Lixte Biotechnology by 83.6% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after purchasing an additional 42,530 shares during the period. 5.10% of the stock is currently owned by hedge funds and other institutional investors.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.